EyePoint Pharmaceuticals, Inc.
EYPT
$5.55
-$0.12-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.27M | 45.71M | 50.39M | 50.02M | 46.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.27M | 45.71M | 50.39M | 50.02M | 46.02M |
| Cost of Revenue | -3.27M | 25.03M | 13.99M | 11.68M | -4.96M |
| Gross Profit | 46.54M | 20.68M | 36.40M | 38.34M | 50.98M |
| SG&A Expenses | 54.99M | 53.11M | 50.48M | 51.79M | 52.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 189.13M | 162.68M | 149.01M | 136.85M | 121.09M |
| Operating Income | -145.85M | -116.97M | -98.62M | -86.83M | -75.07M |
| Income Before Tax | -130.78M | -103.49M | -86.74M | -78.83M | -70.71M |
| Income Tax Expenses | 90.00K | 83.00K | 83.00K | 83.00K | 83.00K |
| Earnings from Continuing Operations | -130.87 | -103.57 | -86.82 | -78.92 | -70.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.87M | -103.57M | -86.82M | -78.92M | -70.80M |
| EBIT | -145.85M | -116.97M | -98.62M | -86.83M | -75.07M |
| EBITDA | -144.31M | -115.78M | -97.73M | -86.17M | -74.60M |
| EPS Basic | -2.31 | -2.01 | -1.80 | -1.83 | -1.84 |
| Normalized Basic EPS | -1.44 | -1.25 | -1.12 | -1.12 | -1.13 |
| EPS Diluted | -2.31 | -2.01 | -1.80 | -1.83 | -1.84 |
| Normalized Diluted EPS | -1.44 | -1.25 | -1.12 | -1.12 | -1.13 |
| Average Basic Shares Outstanding | 225.12M | 202.74M | 186.63M | 171.00M | 155.57M |
| Average Diluted Shares Outstanding | 225.12M | 202.74M | 186.63M | 171.00M | 155.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |